Literature DB >> 24851270

Osteoblasts protect AML cells from SDF-1-induced apoptosis.

Kimberly N Kremer, Amel Dudakovic, Meghan E McGee-Lawrence, Rachael L Philips, Allan D Hess, B Douglas Smith, Andre J van Wijnen, Judith E Karp, Scott H Kaufmann, Jennifer J Westendorf, Karen E Hedin.   

Abstract

The bone marrow provides a protective environment for acute myeloid leukemia (AML) cells that often allows leukemic stem cells to survive standard chemotherapeutic regimens. Targeting these leukemic stem cells within the bone marrow is critical for preventing relapse. We recently demonstrated that SDF-1, a chemokine abundant in the bone marrow, induces apoptosis in AML cell lines and in patient samples expressing high levels of its receptor, CXCR4. Here we show that a subset of osteoblast lineage cells within the bone marrow can protect AML cells from undergoing apoptosis in response to the SDF-1 naturally present in that location. In co-culture systems, osteoblasts at various stages of differentiation protected AML cell lines and patient isolates from SDF-1-induced apoptosis. The differentiation of the osteoblast cell lines, MC3T3 and W-20-17, mediated this protection via a cell contact-independent mechanism. In contrast, bone marrow-derived mesenchymal cells, the precursors of osteoblasts, induced apoptosis in AML cells via a CXCR4-dependent mechanism and failed to protect AML cells from exogenously added SDF-1. These results indicate that osteoblasts in the process of differentiation potently inhibit the SDF-1-driven apoptotic pathway of CXCR4-expressing AML cells residing in the bone marrow. Drugs targeting this protective mechanism could potentially provide a new approach to treating AML by enhancing the SDF-1-induced apoptosis of AML cells residing within the bone marrow microenvironment.
© 2014 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24851270      PMCID: PMC4161028          DOI: 10.1002/jcb.24755

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  30 in total

Review 1.  The vascular niche: home for normal and malignant hematopoietic stem cells.

Authors:  P L Doan; J P Chute
Journal:  Leukemia       Date:  2011-09-02       Impact factor: 11.528

2.  AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor.

Authors:  G A Donzella; D Schols; S W Lin; J A Esté; K A Nagashima; P J Maddon; G P Allaway; T P Sakmar; G Henson; E De Clercq; J P Moore
Journal:  Nat Med       Date:  1998-01       Impact factor: 53.440

3.  In vitro maintenance of highly purified, transplantable hematopoietic stem cells.

Authors:  K A Moore; H Ema; I R Lemischka
Journal:  Blood       Date:  1997-06-15       Impact factor: 22.113

4.  Single-step separation of red blood cells. Granulocytes and mononuclear leukocytes on discontinuous density gradients of Ficoll-Hypaque.

Authors:  D English; B R Andersen
Journal:  J Immunol Methods       Date:  1974-08       Impact factor: 2.303

5.  Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins.

Authors:  M Konopleva; S Konoplev; W Hu; A Y Zaritskey; B V Afanasiev; M Andreeff
Journal:  Leukemia       Date:  2002-09       Impact factor: 11.528

6.  Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region.

Authors:  Fumihiko Ishikawa; Shuro Yoshida; Yoriko Saito; Atsushi Hijikata; Hiroshi Kitamura; Satoshi Tanaka; Ryu Nakamura; Toru Tanaka; Hiroko Tomiyama; Noriyuki Saito; Mitsuhiro Fukata; Toshihiro Miyamoto; Bonnie Lyons; Koichi Ohshima; Naoyuki Uchida; Shuichi Taniguchi; Osamu Ohara; Koichi Akashi; Mine Harada; Leonard D Shultz
Journal:  Nat Biotechnol       Date:  2007-10-21       Impact factor: 54.908

Review 7.  Regulation of Wnt/β-catenin signaling within and from osteocytes.

Authors:  Travis A Burgers; Bart O Williams
Journal:  Bone       Date:  2013-03-05       Impact factor: 4.398

8.  Recombinant human bone morphogenetic protein-2 induces osteoblastic differentiation in W-20-17 stromal cells.

Authors:  R S Thies; M Bauduy; B A Ashton; L Kurtzberg; J M Wozney; V Rosen
Journal:  Endocrinology       Date:  1992-03       Impact factor: 4.736

9.  The TPO/c-MPL pathway in the bone marrow may protect leukemia cells from chemotherapy in AML Patients.

Authors:  Zeng Dong-Feng; Liu Ting; Zhang Yong; Chang Cheng; Zhang Xi; Kong Pei-Yan
Journal:  Pathol Oncol Res       Date:  2013-10-02       Impact factor: 3.201

Review 10.  The bone marrow stem cell niche grows up: mesenchymal stem cells and macrophages move in.

Authors:  Armin Ehninger; Andreas Trumpp
Journal:  J Exp Med       Date:  2011-03-14       Impact factor: 14.307

View more
  17 in total

1.  Highly multiplexed proteomic assessment of human bone marrow in acute myeloid leukemia.

Authors:  Haydar Çelik; Katherine E Lindblad; Bogdan Popescu; Gege Gui; Meghali Goswami; Janet Valdez; Christin DeStefano; Catherine Lai; Julie Thompson; Jack Y Ghannam; Giovanna Fantoni; Angélique Biancotto; Julián Candia; Foo Cheung; Gauthaman Sukumar; Clifton L Dalgard; Richard H Smith; Andre Larochelle; Laura W Dillon; Christopher S Hourigan
Journal:  Blood Adv       Date:  2020-01-28

2.  Endosteal vessel integrity: a new therapeutic goal in acute myeloid leukemia?

Authors:  Paolo Bernasconi; Oscar Borsani
Journal:  Stem Cell Investig       Date:  2018-10-22

3.  Histone Deacetylase 3 Deletion in Mesenchymal Progenitor Cells Hinders Long Bone Development.

Authors:  Marina Feigenson; Lomeli Carpio Shull; Earnest L Taylor; Emily T Camilleri; Scott M Riester; Andre J van Wijnen; Elizabeth W Bradley; Jennifer J Westendorf
Journal:  J Bone Miner Res       Date:  2017-09-18       Impact factor: 6.741

Review 4.  Targeting the microenvironment in acute myeloid leukemia.

Authors:  Armin Rashidi; Geoffrey L Uy
Journal:  Curr Hematol Malig Rep       Date:  2015-06       Impact factor: 3.952

5.  Targeted positron emission tomography imaging of CXCR4 expression in patients with acute myeloid leukemia.

Authors:  Peter Herhaus; Stefan Habringer; Kathrin Philipp-Abbrederis; Tibor Vag; Carlos Gerngross; Margret Schottelius; Julia Slotta-Huspenina; Katja Steiger; Torben Altmann; Tanja Weißer; Sabine Steidle; Markus Schick; Laura Jacobs; Jolanta Slawska; Catharina Müller-Thomas; Mareike Verbeek; Marion Subklewe; Christian Peschel; Hans-Jürgen Wester; Markus Schwaiger; Katharina Götze; Ulrich Keller
Journal:  Haematologica       Date:  2016-05-12       Impact factor: 9.941

6.  Tissue-Nonspecific Alkaline Phosphatase Is Required for MC3T3 Osteoblast-Mediated Protection of Acute Myeloid Leukemia Cells from Apoptosis.

Authors:  Rosalie M Sterner; Kimberly N Kremer; Amel Dudakovic; Jennifer J Westendorf; Andre J van Wijnen; Karen E Hedin
Journal:  J Immunol       Date:  2018-06-18       Impact factor: 5.422

Review 7.  The role and clinical implications of the endosteal niche and osteoblasts in regulating leukemia.

Authors:  S Azizidoost; V Vijay; C R Cogle; E Khodadi; N Saki
Journal:  Clin Transl Oncol       Date:  2017-03-09       Impact factor: 3.405

Review 8.  Targeting the leukemia-stroma interaction in acute myeloid leukemia: rationale and latest evidence.

Authors:  Armin Rashidi; John F DiPersio
Journal:  Ther Adv Hematol       Date:  2016-02

9.  Histone Deacetylase Inhibitors Target the Leukemic Microenvironment by Enhancing a Nherf1-Protein Phosphatase 1α-TAZ Signaling Pathway in Osteoblasts.

Authors:  Kimberly N Kremer; Amel Dudakovic; Allan D Hess; B Douglas Smith; Judith E Karp; Scott H Kaufmann; Jennifer J Westendorf; Andre J van Wijnen; Karen E Hedin
Journal:  J Biol Chem       Date:  2015-10-21       Impact factor: 5.157

10.  Disruption of Annexin II /p11 Interaction Suppresses Leukemia Cell Binding, Homing and Engraftment, and Sensitizes the Leukemia Cells to Chemotherapy.

Authors:  Anilkumar Gopalakrishnapillai; E Anders Kolb; Priyanka Dhanan; Robert W Mason; Andrew Napper; Sonali P Barwe
Journal:  PLoS One       Date:  2015-10-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.